X
    X
    X
    X

    Chicago Partner Tom Bush Provides Insight on Recent US Vitamin C Decision Favoring Chinese Firms

    Articles

    Chicago’s Tom Bush, Partner and Co-Chair of the Firm's Antitrust Litigation Practice Group, was recently quoted in Policy and Regulatory Report on the US Court of Appeals for the Second Circuit’s recent verdict in a price-fixing judgment in a civil class action suit imposed against two Chinese Vitamin C manufacturers and said the decision “certainly expands the ability of Chinese companies to invoke a comity defense.” On September 20th, the Second Circuit voided a 147.8M price-fixing verdict against Hebei Welcome Pharmaceutical and North China Pharmaceutical Group noting the district court should have deferred to China’s interpretation of its own laws.

    Bush also said the Second Circuit’s decision does not necessarily remove the opportunity of success in other private litigation price-fixing suits but it “certainly raises the barrier.”

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.